Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 5
1985 8
1986 49
1987 25
1988 13
1989 15
1990 46
1991 16
1992 21
1993 22
1994 34
1995 29
1996 30
1997 30
1998 38
1999 50
2000 56
2001 59
2002 56
2003 61
2004 48
2005 48
2006 52
2007 61
2008 53
2009 70
2010 72
2011 59
2012 79
2013 80
2014 83
2015 97
2016 102
2017 85
2018 77
2019 87
2020 102
2021 129
2022 109
2023 103
2024 118
2025 127
2026 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,308 results

Results by year

Filters applied: . Clear all
Page 1
Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review.
Muresan L, Cismaru G, Muresan C, Rosu R, Gusetu G, Puiu M, Mada RO, Martins RP. Muresan L, et al. Ann Pharm Fr. 2022 Sep;80(5):617-634. doi: 10.1016/j.pharma.2022.01.007. Epub 2022 Jan 31. Ann Pharm Fr. 2022. PMID: 35093388 Free article.
The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and ventricular arrhythmias. MATERIAL AND METHODS: Using the keywords "bisoprolol" and "arrhythmias" or "atrial fibrillation" or "ventricular …
The aim of this study was to analyze the current existing evidence for bisoprolol for the treatment of both supraventricular and vent …
Therapeutic Properties of Highly Selective beta-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease.
AlHabeeb W, Mrabeti S, Abdelsalam AAI. AlHabeeb W, et al. Cardiovasc Drugs Ther. 2022 Oct;36(5):959-971. doi: 10.1007/s10557-021-07205-y. Epub 2021 Jun 9. Cardiovasc Drugs Ther. 2022. PMID: 34106365 Free PMC article. Review.
In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influence the effectiveness of nebivolol in the management of HFrEF, IHD and hypertension. In this article, we review the therapeutic properties o …
In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influe …
Bisoprolol: A comprehensive profile.
Bakheit AH, Ali R, Alshahrani AD, El-Azab AS. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:51-89. doi: 10.1016/bs.podrm.2020.07.006. Epub 2020 Sep 8. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461700
The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appearance, its uses, applications, and methods for the preparation are outlined. ...The mass fragmentation pattern of bisoprolol fumarat …
The present study describes a comprehensive profile of Bisoprolol including detailed nomenclature; formulae, elemental analysis, appe …
Pharmacogenetic polymorphisms affecting bisoprolol response.
Castaño-Amores C, Díaz-Villamarín X, Pérez-Gutiérrez AM, Antúnez-Rodríguez A, Pozo-Agundo A, Moreno-Escobar E, Sánchez-Ramos JG, Martínez-González LJ, Dávila-Fajardo CL. Castaño-Amores C, et al. Biomed Pharmacother. 2021 Oct;142:112069. doi: 10.1016/j.biopha.2021.112069. Epub 2021 Aug 27. Biomed Pharmacother. 2021. PMID: 34470728 Free article.
The ADRB1 Arg389Gly (rs1801253) was the most studied genetic polymorphism and it seems to influence the response to bisoprolol, although studies are inconclusive. Even, we performed a meta-analysis about its influence on systolic/diastolic blood pressure in patients treate …
The ADRB1 Arg389Gly (rs1801253) was the most studied genetic polymorphism and it seems to influence the response to bisoprolol, altho …
[Elevated augmentation index].
Baulmann J, Schunkert H. Baulmann J, et al. Dtsch Med Wochenschr. 2012 Feb;137(6):281-2. doi: 10.1055/s-0031-1298801. Epub 2012 Jan 31. Dtsch Med Wochenschr. 2012. PMID: 22294114 German. No abstract available.
Bisoprolol-induced nightmares.
Kuriyama S. Kuriyama S. J Hum Hypertens. 1994 Sep;8(9):730. J Hum Hypertens. 1994. PMID: 7807505 No abstract available.
Comparison of nebivolol, carvedilol, and bisoprolol for adverse clinical outcomes among patients with heart failure-a real-world nationwide investigation.
Hu WS, Lin CL. Hu WS, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):10295-10303. doi: 10.1007/s00210-025-03855-z. Epub 2025 Feb 19. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39969604
Both carvedilol and bisoprolol cohorts had a higher risk of readmission for HF than the non-BB cohort (carvedilol: adjusted HR = 1.13, 95% CI = 1.10-1.15; bisoprolol: adjusted HR = 1.17, 95% CI = 1.16-1.19). ...There were higher risks of CV (carvedilol: adjusted HR …
Both carvedilol and bisoprolol cohorts had a higher risk of readmission for HF than the non-BB cohort (carvedilol: adjusted HR = 1.13 …
Effect of Bisoprolol on the Level of Dabigatran.
Nehaj F, Sokol J, Ivankova J, Mokan M, Mokan M. Nehaj F, et al. Am J Ther. 2020 Mar/Apr;27(2):e159-e164. doi: 10.1097/MJT.0000000000000786. Am J Ther. 2020. PMID: 30074534
BACKGROUND: Many patients receiving dabigatran treatment might also require bisoprolol therapy. However, there is a possibility that bisoprolol as significant P-glycoprotein inhibitor might interact with dabigatran. ...The impact of bisoprolol on dabigatran c …
BACKGROUND: Many patients receiving dabigatran treatment might also require bisoprolol therapy. However, there is a possibility that …
No benefit from bisoprolol for COPD.
[No authors listed] [No authors listed] Drug Ther Bull. 2025 Jun 30;63(7):99. doi: 10.1136/dtb.2025.000008. Drug Ther Bull. 2025. PMID: 39971479
Overview of: Devereux G, Cotton S, Nath M, et al Bisoprolol in patients with chronic obstructive pulmonary disease at high risk of exacerbation: the BICS randomized clinical trial. ...
Overview of: Devereux G, Cotton S, Nath M, et al Bisoprolol in patients with chronic obstructive pulmonary disease at high risk of ex …
Bisoprolol: a review of its use in chronic heart failure.
McGavin JK, Keating GM. McGavin JK, et al. Drugs. 2002;62(18):2677-96. doi: 10.2165/00003495-200262180-00017. Drugs. 2002. PMID: 12466013 Review.
Bisoprolol is a highly selective beta(1)-adrenoceptor antagonist. Administration of bisoprolol to patients with chronic heart failure is associated with increases in left ventricular function and reductions in heart rate; increases in heart rate variability are also …
Bisoprolol is a highly selective beta(1)-adrenoceptor antagonist. Administration of bisoprolol to patients with chronic heart …
2,308 results